… Lilly and ProQR to Expand RNAEditing Collaboration New agreement supports the discovery … in September 2021, applied ProQR’s proprietary Axiomer® RNAediting platform to target disorders of the liver and …
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora